Short Interest in Helius Medical Technologies, Inc. (NASDAQ:HSDT) Decreases By 75.0%

Helius Medical Technologies, Inc. (NASDAQ:HSDT) was the target of a large decline in short interest during the month of March. As of March 31st, there was short interest totalling 16,600 shares, a decline of 75.0% from the March 15th total of 66,300 shares. Based on an average daily volume of 2,420,000 shares, the short-interest ratio is presently 0.0 days. Approximately 0.5% of the shares of the stock are short sold.

Helius Medical Technologies Price Performance

HSDT stock opened at $0.30 on Tuesday. Helius Medical Technologies has a 1 year low of $0.27 and a 1 year high of $6.08. The firm has a market capitalization of $1.84 million, a PE ratio of -0.05 and a beta of 1.27. The business has a 50 day simple moving average of $0.44 and a 200-day simple moving average of $0.55.

Helius Medical Technologies (NASDAQ:HSDT) last issued its earnings results on Tuesday, March 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.09). The company had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.10 million. Helius Medical Technologies had a negative return on equity of 244.82% and a negative net margin of 1,764.74%.

Institutional Trading of Helius Medical Technologies

An institutional investor recently bought a new position in Helius Medical Technologies stock. Grant Private Wealth Management Inc acquired a new position in Helius Medical Technologies, Inc. (NASDAQ:HSDT) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 37,193 shares of the company’s stock, valued at approximately $25,000. Grant Private Wealth Management Inc owned 1.00% of Helius Medical Technologies as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 18.63% of the company’s stock.

Helius Medical Technologies Company Profile

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.